Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 122.22% from the stock’s current price. HC Wainwright also issued estimates for Anixa Biosciences’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Several other brokerages also recently weighed in on ANIX. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. Maxim Group started coverage on Anixa Biosciences in a report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective for the company.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.15 on Tuesday. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The business has a fifty day moving average price of $2.95 and a 200 day moving average price of $3.01. The stock has a market capitalization of $101.42 million, a P/E ratio of -8.08 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). As a group, equities research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Activity at Anixa Biosciences

In other news, CEO Amit Kumar bought 43,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock valued at $177,021 in the last three months. 25.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after acquiring an additional 3,900 shares during the period. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences during the third quarter worth $34,000. Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the fourth quarter worth $26,000. LPL Financial LLC lifted its position in Anixa Biosciences by 37.2% during the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares during the period. Finally, Westside Investment Management Inc. boosted its holdings in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.